Molnupiravir: A new candidate for COVID‐19 treatment
F Pourkarim, S Pourtaghi‐Anvarian… - Pharmacology …, 2022 - Wiley Online Library
The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …
and has rapidly spread to many countries around the world. The effective pharmacotherapy …
Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management
COVID-19 pandemic is a serious concern in the new era. Acute respiratory distress
syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even …
syndrome (ARDS), and lung failure are the main lung diseases in COVID-19 patients. Even …
Renin‐angiotensin system inhibitors in patients with COVID‐19: a meta‐analysis of randomized controlled trials led by the international society of hypertension
Background Published randomized controlled trials are underpowered for binary clinical
end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in …
end points to assess the safety and efficacy of renin‐angiotensin system inhibitors (RASi) in …
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
MJ Jardine, SS Kotwal, A Bassi, C Hockham, M Jones… - Bmj, 2022 - bmj.com
Objective To determine whether disrupting the renin angiotensin system with angiotensin
receptor blockers will improve clinical outcomes in people with covid-19. Design CLARITY …
receptor blockers will improve clinical outcomes in people with covid-19. Design CLARITY …
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double …
Background COVID-19 morbidity and mortality remains high and the need for safe and
effective drugs continues despite vaccines. Methods Double-blind, placebo-controlled, multi …
effective drugs continues despite vaccines. Methods Double-blind, placebo-controlled, multi …
Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations
LA Méndez-García, G Escobedo… - Frontiers in Cellular …, 2022 - frontiersin.org
SARS-CoV-2 causes COVID-19, which has claimed millions of lives. This virus can infect
various cells and tissues, including the brain, for which numerous neurological symptoms …
various cells and tissues, including the brain, for which numerous neurological symptoms …
Effects of renin–angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: a meta-analysis of randomized controlled trials
J Yin, C Wang, X Song, X Li… - American Journal of …, 2022 - academic.oup.com
BACKGROUND There is controversy over the effects of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on the prognosis in patients …
inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on the prognosis in patients …
Emerging viral infections and the potential impact on hypertension, cardiovascular disease, and kidney disease
Viruses are ubiquitous in the environment and continue to have a profound impact on
human health and disease. The COVID-19 pandemic has highlighted this with impressive …
human health and disease. The COVID-19 pandemic has highlighted this with impressive …
All-solid-state paper-based potentiometric combined sensor modified with reduced graphene oxide (rGO) and molecularly imprinted polymer for monitoring losartan …
A cost-effective, highly selective and sensitive paper-based potentiometric combined sensor
for losartan potassium drug (LOS) is fabricated, characterized and used for the drug …
for losartan potassium drug (LOS) is fabricated, characterized and used for the drug …
Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients
Introduction Hypertension is a common chronic disorder in patients hospitalized for
coronavirus disease 2019 (COVID-19). Furthermore, an exaggerated cardiovascular …
coronavirus disease 2019 (COVID-19). Furthermore, an exaggerated cardiovascular …